GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
Achieved profitability milestone with third quarter adjusted net income1 of $1.2MReported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test revenueExpanded third quarter 2024 adjusted gross margins2 to 64%Raising guidance to deliver between $284M and $290M in FY 2024 revenueGeneDx to host conference call today at 8:30 a.m. ET STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2024.“We delivered 77% growth on exome and genome revenues in Q3 and have reached the point of profitability, a significant milestone in our company’s history,” said Katherine Stueland, CEO of GeneDx. “Our advancements in genomics are redefining the standard of care, setting new industry standards for clinical utility and economic efficiency, and shortening the time to a diagnosis for thousands of families. With
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU PatientsBusiness Wire
- GeneDx to Participate in 45th Annual TD Cowen Health Care ConferenceBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGSPR Newswire
- GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate TreatmentBusiness Wire
- GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025Business Wire
WGS
Earnings
- 10/29/24 - Miss
WGS
Sec Filings
- 2/12/25 - Form SCHEDULE
- 2/7/25 - Form 4
- 2/5/25 - Form SCHEDULE
- WGS's page on the SEC website